First-line therapies for
antimicrobial resistance

Our Products and Pipeline

There is a growing scarcity of novel and effective broad-spectrum antibiotics for the treatment of bacterial infections.

Slide to view more

Research
Preclinical
Phase 1
Phase 2
Phase 3
Registration
Marketed*
ABSSSIl Oral and IV Dosing
CABP Oral and IV Dosing
Non-Tuberculous Mycobacteria (NTM) Orphan Designation
Post Exposure Prophylaxis of Pulmonary Anthrax
Treatment of Pulmonary Anthrax
Military Research
Anthrax Programs Conducted Through
The FDA Animal Rule Program
ex-US+
US
(Global*)
Research
Preclinical
Phase 1
Phase 2
Phase 3
Registration
Marketed*
Commercial Rights
ABSSSI (IV & Oral)
ABSSSI (Oral only Loading Dose)
CABP (IV & Oral)
Non-Tuberculous Mycobacteria (NTM)   (Orphan)
CABP PK Study for Oral-only Labelling
Pulmonary Anthrax; Project BioShield
FDA Animal Rule Applies
Approved
Inflamatory Acne (Acne Vulgaris)

*Paratek has global rights with the exception of the greater China region where Paratek has entered into a collaboration agreement with Zai Lab (Shanghai) Co., Ld.

AMR is a Global Health Threat

Antimicrobial Resistance (AMR)  is life-threatening, costly and present in every country in the world.

Drug-resistant infections cost the US an annual $20 billion in excess healthcare costs and $35 billion in lost productivity. According to recent research, it's estimated that up to 160,000 in US die from antibiotic resistance per year and almost three-quarters of a million people around the globe annually; by 2050 that could grow to 10 million every year if the trend isn’t slowed.

Paratek is fighting the AMR pandemic.

NUZYRA®

NUZYRA® (omadacycline), approved by the FDA, is a once-daily oral and intravenous antibiotic for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by select susceptible microorganisms. See Full Prescribing Information here.

Paratek remains committed to the further study of NUZYRA in additional areas on unmet medical need. For a full list of ongoing clinical studies, please visit clinicaltrials.gov.

Department of Defense

Under a broad-based Project BioShield contract with  Biomedical Advanced Research and Development Authority, or BARDA, which is a part of the United States Department of Health and Human Services and the Office of the Assistant Secretary for Preparedness and Response, NUZYRA® is being studied against anthrax, a pathogenic agent that potentially causes an infectious disease of public health and biodefense importance.

Global Partnerships

Paratek owns world-wide rights to omadacycline. Paratek has entered into a collaboration with Zai Lab (Shanghai) Co., Ltd., to support the development and commercialization of omadacycline for patients in Greater China.

Learn more about NUZYRA® including important safety information, and see our patent portfolio.

SEYSARA®

The FDA approved SEYSARA® (sarecycline) in October 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. SEYSARA® is marketed by Almirall, LLC in the U.S.  For complete prescribing information, including the Warnings and Precautions, please visit here.

Global Partnerships

Paratek retains rest of world (outside of the U.S. and greater China region) rights to sarecycline and is currently exploring partnership opportunities to develop and approve sarecycline in appropriate markets.

Partnerships

Interested in a partnership for rights in other regions? Connect with our business development team or call us at 1-617-807-6600.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Clinical & Prescribing Information

Click here to learn more about prescribing NUZYRA® to your patients.

Download
Global Partnerships

Paratek has retained rest of world (outside of the U.S.) rights to sarecycline and is currently exploring partnership opportunities to develop and approve sarecycline in appropriate markets.

Our Product
NUZYRA®  is an FDA-approved tetracycline-class antibiotic designed to address a significant unmet need for adult patients with CABP and ABSSSI caused by susceptible bacteria.
Learn More
Groundbreaking Innovators
A disciplined team with proven capabilities in developing and commercializing new treatment options for complex medical issues.

Meet Our Team
Powered by You
Our employees are experienced, committed, and driven to build a company that saves lives. Learn more about how you can join our team.
View Open Roles